Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
November 13, 2024 07:00 ET
|
Passage Bio
Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from...
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
November 06, 2024 07:00 ET
|
Passage Bio
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
October 24, 2024 07:00 ET
|
Passage Bio
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) Nonclinical data showed PBFT02 improved...
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 23, 2024 07:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
September 16, 2024 07:00 ET
|
Passage Bio
Interim safety and biomarker data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 of PBFT02 achieved robust levels of CSF progranulin in all treated Cohort 1 patients; elevated CSF...
Passage Bio Welcomes Tom Kassberg to Board of Directors
September 10, 2024 07:52 ET
|
Passage Bio
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
August 30, 2024 07:00 ET
|
Passage Bio
PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
August 08, 2024 07:00 ET
|
Passage Bio
Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on...
Passage Bio to Participate in Upcoming Investor Conferences
August 06, 2024 07:00 ET
|
Passage Bio
PHILADELPHIA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
August 01, 2024 07:00 ET
|
Passage Bio
Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA...